CysC levels were measured in sequential plasma samples from 811 subjects with ADHF who were enrolled in the ASCEND-HF ( Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure ) biomarker sub-study ( randomized to nesiritide therapy vs. placebo ) , and followed for all-cause death ( 180 days ) and recurrent hospital stay ( 30 days ) .